VCs take note: Sofinnova pairs portfolio with Nvidia AI muscle
Paris-based firm gets an AI capacity advantage others may aim to emulate
Two years after launching a digital medicine investment strategy focused on the convergence of biology, data and computing, Sofinnova Partners is hoping to supercharge its portfolio companies by leveraging access to Nvidia’s AI infrastructure. As demand for computational power in drug discovery intensifies, Sofinnova’s move could set a precedent for for biotech VCs.
Sofinnova announced Wednesday a partnership with Nvidia Corp. (NASDAQ:NVDA) that provides its portfolio companies with graphics processing unit (GPU) capacity credits to access computational power via Nvidia’s DGX Cloud Lepton — a platform that brings together cloud AI providers and the most advanced GPU computing capacity to provide on-demand access to a global network of GPUs...